American Association for Cancer Research
19406207capr110547-sup-stab_1c_95k.pdf (95.88 kB)

Supplementary Table 1C from Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation

Download (95.88 kB)
journal contribution
posted on 2023-04-03, 19:04 authored by Diala Abd-Rabbo, Christine Abaji, Guillaume B. Cardin, Abdelali Filali-Mouhim, Caroline Arous, Lise Portelance, Enrique Escobar, Sophie Cloutier, Patricia N. Tonin, Diane M. Provencher, Anne-Marie Mes-Masson, Christine M. Maugard

PDF file - 95K, Molecular profile differentiating BRCA1- from BRCA2-mutated NOSEs



We hypothesized that the transcriptome of primary cultures of morphologically normal ovarian surface epithelial cells could be altered by the presence of a heterozygous BRCA1 or BRCA2 mutation. We aimed to discover early events associated with ovarian carcinogenesis, which could represent putative targets for preventive strategies of this silent killer tumor. We identified the first molecular signature associated with French Canadian BRCA1 or BRCA2 founder mutations in morphologically normal ovarian epithelial cells. We discovered that wild-type and mutated BRCA2 allelic transcripts were expressed not only in morphologically normal but also in tumor cells from BRCA2-8765delAG carriers. Further analysis of morphologically normal ovarian and tumor cells from BRCA1-4446C>T carriers lead to the same observation. Our data support the idea that one single hit in BRCA1 or BRCA2 is sufficient to alter the transcriptome of phenotypically normal ovarian epithelial cells. The highest level of BRCA2-mutated allele transcript expression was measured in cells originating from the most aggressive ovarian tumor. The penetrance of the mutation and the aggressiveness of the related tumor could depend on a dosage effect of the mutated allele transcript. Cancer Prev Res; 5(5); 765–77. ©2012 AACR.

Usage metrics

    Cancer Prevention Research



    Ref. manager